Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence

Background and Purpose Current guidelines do not recommend the use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who receive direct oral anticoagulants. While the humanized monoclonal antibody idarucizumab can quickly reverse the anticoagulant effects...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CNS drugs 2017-09, Vol.31 (9), p.747-757
Hauptverfasser:	Pikija, Slaven, Sztriha, Laszlo K., Sebastian Mutzenbach, J., Golaszewski, Stefan M., Sellner, Johann
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Aged Aged, 80 and over Animals Antibodies, Monoclonal, Humanized - therapeutic use Anticoagulants Antithrombins - administration & dosage Antithrombins - adverse effects Bleeding Brain Ischemia - drug therapy Dabigatran - administration & dosage Dabigatran - adverse effects Drug dosages Female Heart Hemorrhage Hemorrhage - chemically induced Humans Hypersensitivity Intravenous administration Ischemia Male Medicine Medicine & Public Health Monoclonal antibodies Neurology Neurosciences Patients Pharmacotherapy Practice Guidelines as Topic Prevention Psychiatry Psychopharmacology Reperfusion Stroke Stroke - drug therapy Systematic Review t-Plasminogen activator Thrombin Thrombolysis Thrombosis Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!